When is Aiforia the better choice?

Not tied to an assay maker: the models run on whole slide images independent of any single assay vendor, unlike Visiopharm's APPs, which are validated to and sold alongside Agilent assays and the Omnis platform. A model building engine plus broad suites: Aiforia Create for developing custom models, alongside clinical coverage across five tumor types and lymph node. Vendor stability visibility from its Helsinki listing, which most private competitors here do not offer.

When is Visiopharm the better choice?

The deepest IVDR clearance accumulation in this group: the PD-L1 application is its ninth IVDR clearance, a substantial certified portfolio under IVDR's stricter evidence bar. Assay validated integration for Agilent laboratories: the APPs are validated to Agilent assays and the Omnis platform and sold as the Visiopharm Diagnostic Package, giving a second procurement route. An unusually candid autonomy framing: its PD-L1 validation tested standalone algorithm analysis and algorithm assisted interpretation as distinct conditions, rather than reporting only the flattering pairing.

Head-to-Head

Aiforia vs Visiopharm

Last VerifiedJuly 22, 2026

Verdict

Both are CE marked biomarker vendors with no FDA clearance and an A on AI centrality, so the split is breadth and assay independence versus regulatory volume and assay integration. If you want multi tumor suites that are not tied to one assay maker, plus a model building engine, start with Aiforia. If your laboratory runs Agilent assays and you want biomarker algorithms validated to them, start with Visiopharm. Aiforia spans five tumor types plus lymph node and offers Aiforia Create for building models. Visiopharm holds the deepest accumulation of IVDR clearances in this group, with the PD-L1 application marking its ninth, and sells its algorithms validated to Agilent assays and the Omnis platform, a benefit for Agilent shops and a constraint for everyone else.

Select Aiforia if

Not tied to an assay maker: the models run on whole slide images independent of any single assay vendor, unlike Visiopharm's APPs, which are validated to and sold alongside Agilent assays and the Omnis platform.
A model building engine plus broad suites: Aiforia Create for developing custom models, alongside clinical coverage across five tumor types and lymph node.
Vendor stability visibility from its Helsinki listing, which most private competitors here do not offer.

Select Visiopharm if

The deepest IVDR clearance accumulation in this group: the PD-L1 application is its ninth IVDR clearance, a substantial certified portfolio under IVDR's stricter evidence bar.
Assay validated integration for Agilent laboratories: the APPs are validated to Agilent assays and the Omnis platform and sold as the Visiopharm Diagnostic Package, giving a second procurement route.
An unusually candid autonomy framing: its PD-L1 validation tested standalone algorithm analysis and algorithm assisted interpretation as distinct conditions, rather than reporting only the flattering pairing.

Attribute Matrix

Side-by-Side

Axis	A Aiforia	V Visiopharm
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Disclosure

Both are CE-IVD only with no FDA clearance, neither publishes pricing or a security attestation, and both report concordance and efficiency evidence rather than patient outcome. One portfolio caveat on Visiopharm a buyer should catch: its prostate APP is supplied by DeepBio and carries the older IVDD mark rather than IVDR, a lower evidence bar, so the certified portfolio is not uniform, and its validation is asserted across three sites without demographic subgroup analysis. Aiforia's efficiency figures are vendor quoted and not independently verified, and its integration is asserted through partnerships rather than an enumerated connector list, which is why it grades lower on interoperability. Coverage in both cases depends on the specific tumor type, antibody clone, and assay in use at a given laboratory rather than on the vendor name.